Work

Supplementary Figure 2 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 2. MAPK pathway signature is specifically inhibited on treatment (A). Differential expression of 11 PROGENy (pathway) scores between pre and post-treatment samples (B). Only MAPK and EGFR scores are statistically significant (rank-sum test).

DOI: 10.1158/1078-0432.22479702.v1

Authors: Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, Patricia LoRusso, Johanna Bendell, Shih-Min A. Huang, Marie-Claire Wagle, Kwame Okrah, Lichuan Liu, Elaine Murray, Sandra M. Sanabria-Bohorquez, Michael Tagen, Hatem Dokainish, Lars Mueller, Howard Burris

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361938952

Cites:

Cited by:

Related to: 10